

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFN in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

NCT06650852

Status	RECRUITING
Phase	Phase 2
Sponsor	Brii Biosciences Limited
Enrollment	250 participants

Key Eligibility Criteria

Inclusion (5)

- Male or female aged 18-60 years.
- Body mass index ≥ 18 kg/m² and ≤ 32 kg/m².
- Chronic HBV infection for ≥ 6 months.
- On NRTI therapy with HBV DNA \leq LLOQ for ≥ 6 months.
- Serum ALT and AST \leq ULN at screening visit.

Exclusion (9)

- Any clinically significant chronic medical conditions other than chronic HBV infection that makes the participant unsuitable for participation in the study.
- Significant liver fibrosis or cirrhosis.
- History of clinically significant chronic liver disease from any cause other than chronic HBV infection.
- History of hepatic decompensation.
- Diagnosed or suspected hepatocellular carcinoma.
- ... and 4 more (see full listing online)

Locations (14 total)

Investigative Site 86001, Beijing, Beijing Municipality, China
Investigative Site 86003, Beijing, Beijing Municipality, China
Investigative Site 86004, Beijing, Beijing Municipality, China
... and 11 more locations